Review Article
Management of Advanced and Metastatic Prostate Cancer: A Need for a Sub-Saharan Guideline
Table 1
The demographics, biodata, staging presentation, PSA, and Gleason grade group of patients with prostate cancer in sub-Saharan nations.
| Study | No. of patients | Mean age in years | Age range in years | Staging presentation | PSA range | Mean PSA | Highest Gleason grade group |
| Diallo et al. (Senegal) [8] | 156 | 75.3 | 52–100 | Advanced/metastatic | 1,300–2,104 | 1991.5 | Group 4 (36%) | Botcho et al. (Togo) [9] | 132 | 71 ± 12.6 | 45–99 | Advanced/metastatic | 5–9,998 | 1373.3 ± 1078 | Groups 3–5 (46%) | Kirakoya et al. (Burkina) [10] | 82 | 68.9 ± 9.5 | 49–95 | 98.6% (T3/T4) 40.2% metastasis | 13–9,224 | 746 | Group 1 (59.7%) | Ndoye et al. (Senegal) [11] | 102 | 71 ± 9 | 51–96 | Advanced/metastatic | 5.88–21,660 | 1447.6 ± 812 | Groups 2–5 | Tengue et al. (Togo) [12] | 232 | 68.5 ± 9.6 | | 82.9% (T3/T4) 75.9% metastasis | | 123.5 | Groups 2-3 (34.5%) | Ekwere and Egbe (Nigeria) [13] | 145 | 66.6 ± 9.8 | 35–88 | 81.4% (T3/T4) | | | | Kaboré et al. (Burkina) [14] | 168 | 68.59 ± 9.41 | 30 to 95 | 86% (T3/T4) | 1–7,421 | 483.3 + 145.4 | Group 1 (60.1%) | Wasike and Magoha (Kenya) [15] | 65 | 67 | 50–100 | 87.5% (T3/T4) | | | Group 4 (39.3%) | Kaboré et al. (Burkina) [16] | 166 | 71.5 | 52–86 | 73.6% (T3/T4) | 8.4–17,850 | 537 | Groups 2-3 (54.7%) | Gueye et al. (Senegal) [17] | 121 | 69 | 52–88 | 41.33% (T3/T4) 5.8% metastasis | 6–578.9 | 72.2 | | Ikuerowo et al. (Nigeria) [18] | 43 | 60.8 | | 40% (T3/T4) 35% metastasis | 0–438.3 | 2.5 | Groups 2–5 (74.4%) | Badmus et al. (Nigeria) [19] | 189 | 68 | 40–100 | 94.2% (T3/T4) 91% metastasis | | 106 ± 187 | | Folasire et al. (Nigeria) [20] | 82 | 67 ± 1.8 | 47–87 | Advanced/metastatic | | | Groups 4-5 (38%) | Yeboah et al. (Ghana) [21] | 699 | 70 ± 0.04 | 41–94 | 25% (T3/T4) 13% metastasis | 2.5–9,900 | 52.5 | Groups 2–5 (67.7%) | Konan et al. (Ivory coast) [22] | 362 | 67.4 | 44–97 | 68.2% metastasis | 0–6000 | 315.0 | Groups 2-3 (48.6%) | Sow et al. (Senegal) [23] | 102 | 71.1 ± 8.6 | 54–88 | Metastatic | PSA nadir | 1,167.7 | Group 3 |
|
|